Tenboron is a clinical stage biopharmaceutical company developing novel carriers for biologically targeted cancer radiotherapy called Boron Neutron Capture Therapy, BNCT. BNCT involves delivering boron-10 atoms selectively to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells.Our proprietary boron carriers have been designed to create a large concentration difference between cancer cells and healthy tissue, thus enhancing the efficacy of BNCT. Our spearhead product, an antibody-boron conjugate TB0010 is currently being prepared for a phase 1b clinical trial. for recurrent head and neck carcinomas.